Table 1 Estimated means and within-group effect sizes for recipients of PMHC across continuous primary and secondary outcomes
Estimated means (95% CI) | Estimated means (95% CI) | Estimated means (95% CI) | Estimated means (95% CI) | Estimated means (95% CI) | Effect size (95% CI) | Effect size (95% CI) | Effect size (95% CI) | Effect size (95% CI) | |
|---|---|---|---|---|---|---|---|---|---|
Baseline | 6 months | 12 months | 24 months | 36 months | 6 months | 12 months | 24 months | 36 months | |
PHQ | 14.88 (14.47, 15.29) | 7.50 (7.03, 7.97) | 7.45 (7.01, 7.89) | 7.34 (6.85, 7.83) | 7.23 (6.60, 7.87) | -1.64 (-1.79, -1.49) | -1.65 (-1.80, -1.50) | -1.67 (-1.83, -1.52) | -1.70 (-1.88, -1.52) |
GAD | 12.10 (11.72, 12.48) | 5.85 (5.47, 6.23) | 5.76 (5.42, 6.11) | 5.59 (5.21, 5.96) | 5.41 (4.91, 5.91) | -1.50 (-1.64, -1.36) | -1.52 (-1.66, -1.38) | -1.57 (-1.71, -1.42) | -1.61 (-1.78, -1.44) |
WSAS | 21.80 (21.09, 22.50) | 13.18 (12.09, 14.26) | 11.79 (10.54, 13.04) | 12.04 (10.77, 13.31) | 10.68 (9.29, 12.08) | -1.11 (-1.28, -0.95) | -1.29 (-1.49, -1.10) | -1.26 (-1.46, -1.07) | -1.44 (-1.65, -1.22) |
EQ-5D-5L | .64 (.62, .66) | .81 (.79, .82) | .81 (.79, .84) | .81 (.79, .83) | .81 (.79, .84) | .81 (.72, .90) | .82 (.73, .90) | .83 (.74, .93) | .85 (.74, .96) |
Item 5 EQ-5D-5L | .16 (.15, .17) | .08 (.08, .09) | .08 (.08, .09) | . .08 (.07, .09) | .08 (.07, .09) | -.84 (-.93, -.75) | -.85 (-.94, -.76) | -.88 (-.98, -.79) | -.91 (-1.03, -.79) |
WEMWBS | 18.21 (17.87, 18.56) | 23.43 (22.95, 23.91) | 23.68 (23.22, 24.14) | 24.20 (23.69, 24.70) | 24.72 (24.06, 25.37) | 1.41 (1.24, 1.57) | 1.47 (1.31, 1.64) | 1.61 (1.43, 1.79) | 1.75 (1.54, 1.97) |